Research & Development
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
29 July 2026 - Biopharmaceutical company Incyte (Nasdaq:INCY) announced on Wednesday that the European Commission has approved Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis w...
RTW Biotech portfolio company Yarrow Bioscience completes merger
29 July 2026 - Life sciences investment company RTW Biotech Opportunities Ltd (LSE: RTW) announced on Wednesday that portfolio company Yarrow Bioscience has completed its merger with VYNE Therapeutics...
Lupin's Diazepam Injection, USP receives US approval
29 July 2026 - India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Tuesday that it has received approval under the Federal Food, Drug, and Cosmetic Act (FD&am...
Auxilium Health changes name to Aeris Biosciences
29 July 2026 - Biomaterials developer Auxilium Health has announced a rebrand and change of name to Aeris Biosciences.The name Aeris is designed to reflect what the company's biomaterials are at ...
Saol Therapeutics' SL1009 (DCA) resubmission accepted by FDA
29 July 2026 - Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has acknowledged the company's resub...
Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184
28 July 2026 - Clinical-stage, AI-native biopharma company Lantern Pharma Inc (NASDAQ:LTRN) said on Tuesday that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 cl...